Introduction {#s1}
============

The West of Scotland Coronary Prevention Study (WOSCOPS) was a randomized placebo-controlled primary prevention trial of pravastatin in middle-aged men.^[@EHT232C1]--[@EHT232C3]^ Five years of treatment with pravastatin reduced the primary outcome of death from coronary heart disease (CHD) or nonfatal myocardial infarction (7.9% on placebo to 5.5% on pravastatin, *P* \< 0.001). Definite or suspected CHD deaths were also reduced (1.9--1.3%, *P* = 0.04) with no increased risk of death from non-cardiovascular causes nor an increase in incident cancers.^[@EHT232C3]^ Post-trial extended follow-up for a further 10 years demonstrated a continued reduction in coronary events with no emerging safety issues. Overall, over 15 years, there was a reduction in all-cause mortality \[hazard ratio, HR = 0.88, 95% CI (0.79--0.99), *P* = 0.03\] and in coronary heart disease death or hospitalization \[HR = 0.75, 95% CI (0.68--0.83), *P* \< 0.001\].^[@EHT232C4]^

A previous cost-effectiveness analysis modelled post-trial benefits only on the basis of deaths prevented due to the reduction of coronary events within the formal 5-year trial.^[@EHT232C5]^

Recently, the cost effectiveness of statin treatment in a primary prevention context has been questioned,^[@EHT232C6]^ as was the use of statins in healthy men.^[@EHT232C7]^ In this extended analysis of the WOSCOPS long-term follow-up, we directly address these issues and incorporate new data on cardiovascular cause-specific reasons for admission to hospital (first and recurrent), non-cardiovascular admissions (including diabetes-related admissions), duration of admission, use of angiography and coronary revascularization, leading to an assessment of the costs and effectiveness of statin treatment in the primary prevention of cardiovascular disease.

Methods {#s2}
=======

Original trial {#s2a}
--------------

The design of WOSCOPS and its follow-up have been described elsewhere.^[@EHT232C1]--[@EHT232C4]^ It was a randomized trial comparing pravastatin (40 mg once daily) with placebo in men, aged 45--64 years, with hypercholesterolaemia who had no evidence of previous myocardial infarction. The trial was approved by the ethics committees of the University of Glasgow and participating health boards in Scotland. Between 1989 and 1991, 6595 men gave written informed consent and were randomized. The average follow-up was 4.9 years with final study visits in May 1995.

Post-trial follow-up {#s2b}
--------------------

The post-trial use of lipid-lowering therapy was similar (38.7 and 35.2% in the pravastatin and placebo arms, respectively) in the two groups during the first 5 years of extended follow-up.^[@EHT232C4]^ All follow-up in this report, both within-trial and post-trial, is from electronic linkage to hospital discharge records, the cancer registry and General Register Office death records using established methods, and includes both first and recurrent events.^[@EHT232C8],[@EHT232C9]^

Outcome determination {#s2c}
---------------------

Outcomes were identified using the International Classification of Diseases codes and Office of Population, Censuses and Surveys Classification of Surgical Operations and Procedures codes until December 2004. Follow-up and record linkage was approved by the ethics committee of the Royal Infirmary, Glasgow and the Privacy Advisory Committee of the National Health Service for Scotland.

Previous analyses^[@EHT232C4]^ focussed on time-to-first event for deaths, incident cancers, and composite cardiovascular outcomes. Here, we have analysed in detail healthcare resource utilization (cause-specific hospital admissions, length of stay and need for coronary investigations, procedures and operations), with the consequent impact on the quality of life, additional healthcare costs resulting from a change in disease status after a hospital admission (referred to herein as 'incremental costs of events') and cost effectiveness. We focussed on cardiovascular admissions involving myocardial infarction, stroke, coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), coronary angiography, any coronary cause (including CABG, PCI, or coronary angiography), and heart failure. Myocardial infarction and stroke events were considered outcomes whether or not they were the reason for admission. Other coronary or heart failure codes had to be the primary discharge diagnosis to be counted. Each admission could be represented more than once across the various outcomes. For the length of stay and cost of the acute admissions, each continuous period of in-patient stay was categorized under the most significant included event, defined hierarchically as a stroke if the period of stay involved a stroke, otherwise as a myocardial infarction, otherwise as heart failure, and otherwise as a coronary event if it involved another coronary reason. The composite of these hospitalizations is described as cardiovascular. Other hospitalizations are classed as non-cardiovascular. Because of recent concerns about increased incidence of diabetes in statin-treated individuals, we specifically identified hospitalizations where diabetes or its complications was given as the reason for admission or as a complicating factor. Because of the reduction in cardiovascular hospital admissions associated with statin use, we analysed diabetes-related admissions overall and within hospital admissions with non-cardiovascular causes.

Statistical methods {#s2d}
-------------------

Cumulative incidence functions, accounting for the competing risk of death from other causes, were used to describe the incidence of events. Cause-specific Cox proportional hazards models were fitted including the treatment group and baseline risk factors as described previously^[@EHT232C4]^ \[age, body mass index, systolic and diastolic blood pressures, high- and low-density lipoprotein cholesterol levels, log-transformed triglyceride level, nitrate use, history of angina, history of diabetes, history of hypertension (all yes or no), smoking status (current, former, never), and a social deprivation score\].^[@EHT232C10]^ Effects of randomized treatment assignment (pravastatin versus placebo) were expressed as HRs with 95% confidence intervals and corresponding *P* values. Although it was plausible that the proportional-hazards assumption would not be valid over the full period of follow-up, we concluded that the estimated HRs would still reflect an average effect over the period.

For the hierarchical groupings of continuous periods of hospital stay, total days of admission and lengths of stay for those admitted to hospital were compared between treatment groups using re-randomization *t*-tests. Re-randomization *t*-tests were used as a precaution because of the highly non-Normal distribution of these data, particularly the large numbers of zero values.

Economic evaluation {#s2e}
-------------------

We evaluated the costs and benefits of the initial 5 years treatment with pravastatin over the full available follow-up period of ∼15 years in a cost-utility analysis, as this allows a comparison with other uses of health care resources. We used the perspective of the NHS for costs and savings, and health benefits \[measured in quality-adjusted life years (QALYs) over the follow-up period of 15 years\] for patients; this is consistent with health technology assessments carried out by NICE.

NHS Scotland staff, blinded to randomized treatment, assigned Health Resource Grouping codes to each acute hospital episode, to enable costing with NHS Scotland Tariff costs.^[@EHT232C11]^ We used current (2012) costs of £9.07^[@EHT232C12]^ for a 3-month prescription for 40 mg pravastatin and calculated drug costs from the months of pravastatin used in the trial. In the post-trial period, the 3% excess of statin treatment in the pravastatin group was extrapolated throughout the follow-up. We assumed two liver function and cholesterol tests at the initial consultation, repeated annually whilst on statin treatment (£1.34/test, plus £31 for the initial doctor consultation and £10/annum for nurse consultations).

*Table [1](#EHT232TB1){ref-type="table"}* shows the incremental costs of events for care after discharge from hospital and was based on a previous Health Technology Assessment (HTA) report^[@EHT232C13]^ and updated to 2011 costs using the Hospital and Community Health Services Index.^[@EHT232C14]^ The incremental costs of events reflect out-patient follow-up, primary and community services and reduce after the first year. For multiple events, only the highest applicable additional healthcare costs was used. Table 1Incremental costs of events and quality of life decrements applied following each type of cardiovascular eventEvent TypeAdditional healthcare costsFirst year after dischargeSecond and subsequent years after dischargeQuality-of-life decrement as percentage of baseline1: Stroke£9248£2486−37.1%2: MI£506£197−24%3: HF£506£197−23%4: Other CHD£197£197−19%

Quality of life was assumed to decline with age according to equation: 1.060--0.004 × age (in years). Quality of life was decremented after each admission using the factors given in *Table [1](#EHT232TB1){ref-type="table"}* and was set to zero at death. The disutilities shown in *Table [1](#EHT232TB1){ref-type="table"}* were taken from the previous HTA report.^[@EHT232C13]^ quality-adjusted life years were calculated over the 15-year horizon of the study.

Cumulative mean costs and QALYs per 1000 patients randomized were calculated for each treatment group and compared using bootstrapping with 5000 replicates to calculate *P* values and 95% confidence intervals. Analyses were repeated after discounting costs and quality-of-life decrements at a rate of 3.5% per annum, reflecting the rate recommended by the UK government.

We created three approximately equal sub-groups on the basis of their estimated cardiovascular risk using the ASSIGN Risk score.^[@EHT232C15]^ Participants with a history of angina or stroke or a positive rose questionnaire for angina were assigned to the highest-risk group.

Results {#s3}
=======

Time-to-first event analyses {#s3a}
----------------------------

Time-to-event analyses are presented in *Table [2](#EHT232TB2){ref-type="table"}* and *Figure [1](#EHT232F1){ref-type="fig"}*. Reflecting within-trial results for fatal and non-fatal cardiovascular outcomes, myocardial infarction risk was reduced by 31% (*P* \< 0.001), CHD admission risk by 26% (*P* \< 0.001), and stroke risk by 19% (*P* = 0.038). There were 31, 27, and 31% reductions in the need for PCI, CABG, and use of angiography (*P* = 0.009, 0.003, and \<0.001, respectively). There was a 43% reduction in the risk of admission for heart failure (*P* = 0.002) and a 28% reduction in overall cardiovascular admissions (*P* \< 0.001). There was no evidence of a difference in the risk of non-cardiovascular admissions \[HR 0.99, 95% CI (0.94, 1.05), *P* = 0.75)\]. Overall hospital admissions associated with diabetes occurred in 142 participants randomized to placebo and 128 randomized to pravastatin \[HR 0.78, 95% CI (0.60, 1.00), *P* = 0.05\]. When restricted to hospital admissions classed as non-cardiovascular, these occurred in 105 and 102 participants in the placebo and pravastatin groups, respectively, *P* = 0.29. *Figure [1](#EHT232F1){ref-type="fig"}*A--D shows the cumulative incidence functions for PCI or CABG, all CHD, heart failure, and stroke admissions. For PCI or CABG and CHD admissions, there is evidence of benefit during the initial trial period with a strong suggestion of ongoing benefit. For stroke, and particularly for heart failure, most of the benefit appears to accumulate in the post-trial period. Table 2Numbers of subjects with at least one event and total numbers of events occurring over a period of approximately 15 years for hospital admissions involving the various types of event (events are not necessarily mutually exclusive), split by randomized treatment groupEvent typePlacebo (*n* = 3293)Pravastatin (*n* = 3302)HR*P* valueSubjectsEventsSubjectsEventsHR (95% CI)MI3694262653110.69 (0.59, 0.81)\<0.0001PCI11913784900.69 (0.52, 0.91)0.0089CABG2092131571590.73 (0.59, 0.90)0.0031Angiography3564172553040.69 (0.59, 0.81)\<0.0001CHD755170758612640.74 (0.66, 0.82)\<0.0001HF8013048690.57 (0.39, 0.81)0.0018Stroke2163411843050.81 (0.67, 0.99)0.038Any CV935213172715980.72 (0.66, 0.80)\<0.0001Non CV2476113622496116800.99 (0.94, 1.05)0.75[^1][^2] Figure 1Cumulative incidence curves for cause specific admission to hospital \[(*A*) for CABG or PCI, (*B*) for CHD, (*C*) for Heart Failure and (*D*) for Stroke\], split by a randomized treatment group.

Days in hospital, mean length of stay {#s3b}
-------------------------------------

During 15 years of follow-up, patients allocated originally to the placebo arm spent 20 447 days in hospital for cardiovascular conditions compared to 14 440 for those allocated to pravastatin (*P* = 0.003) (*Table [3](#EHT232TB3){ref-type="table"}*). There were trends to reductions for all cardiovascular admission subtypes with statistically significant reductions for myocardial infarction and other coronary admissions. Average lengths of stay did not differ between treatment groups, nor did the total length of stay for non-cardiovascular causes. Table 3The table contains the number of subjects, number of events, total length of continuous periods of hospital stay (LOS) and mean length of continuous periods of hospital stayEvent typePlacebo (*n* = 3293)Pravastatin (*n* = 3302)*P*~T~*P*~M~SubjectsEventsTotal LOS (days)Mean LOS (days)SubjectsEventsTotal LOS (days)Mean LOS (days)Any CV93521312044710.6872715981444010.340.00260.80 Stroke216341929626.94184305675425.020.270.78 MI36241635238.4726030124848.29\<0.00010.73 HF76122171314.71476782810.260.0740.17 Other CHD536125259154.7543392543744.710.00220.91Non CV247611362482484.17249611680492984.190.700.90[^3]

Acute admission, incremental costs of events, and drug and monitoring costs {#s3c}
---------------------------------------------------------------------------

In *Table [4](#EHT232TB4){ref-type="table"}*, we present the costs of acute admissions, treatment and monitoring, and the incremental costs of events with and without discounting at 3.5% per annum. Table 4Distribution of participants by numbers of cardiovascular (CV) hospital admissions occurring in long-term follow-up Number of CV hospital admissions01234567\>7Placebo2358453227957036211122Pravastatin257534418483513411614[^4]

Net costs and quality-adjusted life years {#s3d}
-----------------------------------------

Net costs and QALYs are reported in *Table [5](#EHT232TB5){ref-type="table"}*. There was no impact on non-cardiovascular admission costs. We estimated that treatment of 1000 patients for an initial 5 years with pravastatin (40 mg/day) would save the NHS £710 000 (*P* \< 0.001) and generate a gain of 136 QALYs (*P* = 0.017), over 15 years of follow-up. Table 5Total assumed average cost (in £) of hospital care based on HRGs Undiscounted costsDiscounted costsPlacebo (*N* = 3293)Pravastatin (*N* = 3302)Placebo (*N* = 3293)Pravastatin (*N* = 3302)Acute costs Any cardiovascular10 409 0117 888 7097 807 9325 918 407  Stroke2 275 1331 868 2891 642 4181 335 683  MI2 098 5931 540 1311 647 0041 196 578  HF646 103413 505457 378297 868  Other CHD5 389 1824 066 7844 061 1333 088 278Cardiovascular admission additional healthcare costs4 626 8543 357 6663 296 8392 397 851Treatment and monitoring costs--724 074--706 647Acute costs Non-cardiovascular25 275 49125 329 61618 998 23319 036 472[^5]

In the three subgroups defined according to ASSIGN baseline risk, actual 10-year placebo-group risks were estimated for the two outcomes defined by (i) coronary death or non-fatal myocardial infarction (MI) and (ii) coronary or stroke death, MI or stroke hospitalization, or PCI or CABG. The 10-year risks for the (low-, medium-, high-) risk groups were (7.5, 10.1, 17.8%) and (10.3, 17.1, 28.0%) for these two outcomes, respectively. Our analyses by subgroups of baseline risk did not reveal any evidence of heterogeneity in the cost savings or QALYs gained (*Table [6](#EHT232TB6){ref-type="table"}*).

*Figure [2](#EHT232F2){ref-type="fig"}* shows the development of the cardiovascular cost savings and QALY gains over time suggesting ongoing accumulation of benefits at 15 years. In *Figure [3](#EHT232F3){ref-type="fig"}*, we show results of 5000 bootstrap simulations presented in the cost-effectiveness plane defined by the mean cost difference and the mean QALY difference. Figure 2Figures showing the cumulative cardiovascular cost differences (*A*) and mean quality-adjusted life year differences (*B*) for pravastatin group - placebo group over time, with 95% confidence intervals. Estimates are shown as solid lines and 95% confidence bounds as dotted lines. Figure 3Plot of bootstrap results on the cost-effectiveness plane.

Sensitivity analyses {#s3e}
--------------------

Sensitivity analyses (Appendix) suggests that our conclusions are robust to reasonable changes in key parameters. A 25% reduction in admission costs changed the cardiovascular savings per 1000 patients over 15 years from £710 100 in the base case to £555 000. A reduction in the assumed health loss from a cardiovascular event by 25% changed the QALY gain per 1000 patients over 15 years from 136 to 120. The only scenario without net cost savings was where we multiplied the prescribing and monitoring costs by 5. Here, the added cost per 1000 patients was £112 000, and the added cost per QALY gained (£112 000/136) was £824.

Discussion {#s4}
==========

Cardiovascular effects {#s4a}
----------------------

We have significantly extended the results reported previously that show that 5 years of treatment with a statin, in middle-aged hypercholesterolaemic men without a history of myocardial infarction, leads to long-term benefit by reducing coronary and all-cause death and coronary events. The current analysis of health care resource utilization indicated that these benefits were accompanied by a reduction in the risk of a first hospital admission for a cardiovascular event (myocardial infarction, stroke, heart failure, and hospitalizations involving PCI, CABG, or angiography or any other coronary cause). Recurrent cardiovascular events of all such types were reduced with substantially fewer days spent in hospital. To put this in perspective, we estimate that treatment of 1000 WOSCOPS-eligible patients for 5 years would prevent 163 cardiovascular inpatient stays (involving 1836 days in hospital), including 35 myocardial infarctions, 11 strokes, 17 heart failure admissions, and 100 involving other aspects of coronary heart disease (including 14 PCIs, 17 CABGs, and 35 coronary angiograms), over a period of 15 years. The resulting acute cardiovascular hospitalization savings (per 1000 treated with pravastatin) to the NHS are estimated to be £771 881 with additional healthcare costs savings of £388 199, all at a cost of £219 283 for pravastatin treatment (at 2012 prices) and monitoring costs (undiscounted figures), giving the net undiscounted savings of £941 397.

Non-cardiovascular effects {#s4b}
--------------------------

We found no evidence of any increase in hospitalization for non-cardiovascular causes, or in the associated costs. In particular, we found no evidence of any excess in-hospital admissions related to diabetes or its complications.

Interpretation {#s4c}
--------------

Reducing days spent in a hospital for cardiovascular causes and preventing the need for coronary revascularization procedures and surgery have significant benefits for the health service and patients. After discounting, there was a net saving to the NHS over 15 years with an associated gain of QALYs. Analysis of subgroups according to the baseline risk did not identify heterogeneity of these effects across subgroups. The suggestion of longer-term benefits in preventing strokes and heart failure admissions is interesting, possibly as a consequence of preventing earlier coronary events and slowing disease progression and hints at the potential for even greater cost savings and better quality of life in the pravastatin-allocated group with longer follow-up.

Results in a broader context {#s4d}
----------------------------

Interest in the cost-effectiveness of statin treatment, particularly in the primary prevention context, shows no signs of waning. Our analysis adds to existing knowledge in two ways.

First, previous analyses have focussed on model-based extrapolations from trial results, and none had access to actual long-term follow-up data. In WOSCOPS, we had the opportunity to link electronically to comprehensive national databases of hospital discharges and deaths, providing information on estimated costs and benefits over a meaningful period of time, and we were able to derive evidence of cost savings and patient benefits without extrapolating results into very old ages where the complexities of multi-morbidity make typical unvalidated modelling assumptions open to question. Second, our analyses suggest that statins are even more cost-effective in primary prevention than had previously been suspected. While most economic evaluations have concluded that the cost per QALY is within acceptable limits, previous evaluations have not suggested that statin prescribing in this patient group could be cost saving. This, in combination with our risk-based sub-group analyses, raises the prospect that statin treatment could be cost saving at lower levels of risk than was previously suspected.

For example, a previous WOSCOPS economic evaluation,^[@EHT232C5]^ based on a model that extrapolated lifetime benefits only via the prevention of within-trial coronary events, estimated an added cost per life-year gain of £20 375 (1996 prices), which is a much less favourable estimate than that indicated in our current analysis. More recently, an economic evaluation in a low-risk population,^[@EHT232C16]^ was based on a review of trial and Canadian registry data. In a 'low-potency statin' versus 'no statin' comparison, the authors predicted an added cost per QALY of Can\$30 000 (about £20 000) using a lifetime perspective; low risk was defined as a 10-year risk of ≤20% for cardiovascular death or non-fatal MI. For this type of endpoint, the WOSCOPS 10-year placebo risk is 12.8% overall and 7.7, 10.8, and 20.0% in our low-, medium- and high-risk subgroups defined by baseline ASSIGN risk. Their QALY estimates were similar to ours. The difference between our results and those of the Canadian registry study is in the hospital admissions and consequent savings from reducing these over time: the actual rates in our data are much more favourable to statin treatment.

Our results are based on the treatment with pravastatin 40 mg, a drug that is well tolerated but is recognized as being less potent than widely used agents such as atorvastatin and rosuvastatin. It is likely that more potent statins, particularly at higher doses, would confer greater benefits in reducing the cardiovascular risk. However, there are safety issues associated with using more potent statins at the highest doses, and higher doses of statins have been linked recently with an increased risk of new-onset diabetes.^[@EHT232C17]^ In the context of treating younger, lower risk individuals with a statin for a lifetime, the drive to improve a patient\'s cardiovascular risk profile would have to be balanced against issues of tolerability and safety. In WOSCOPS we have reported previously a lower rate of new-onset diabetes in the participants randomized to pravastatin over the 5 years of randomized treatment.^[@EHT232C18]^ The meta-analysis of incident diabetes risk in statin trials,^[@EHT232C17]^ although suggesting a modest overall increase in the risk of diabetes with statin treatment, also suggested an interaction with participant age, with oldest participants having the greatest increase in the risk of diabetes on statin treatment. WOSCOPS participants had the lowest mean age in the meta-analysis. In combination with the fact that we found no suggestion of an increase in diabetes-associated hospital admissions over 15 years of follow-up, we believe that this evidence provides reassurance about the long-term safety of treating middle-aged subjects for 5 years with pravastatin at a dose of 40 mg.

Limitations of our analysis {#s4e}
---------------------------

While there are undoubted strengths in our approach, there are also limitations. Our follow-up spans a period during which the management of cardiovascular events (e.g. the increase in use of coronary revascularization) and even event definitions (myocardial infarction) changed. We have avoided the issue of trends in hospital length of stay by using a cost per event reflecting current practice in many countries. Record linkage is subject to error, and there is a possibility that some events have been missed and some wrongly assigned and that coding variation may have mis-assigned reasons for admission. However, we believe that these issues are minor and if anything would add noise and serve only to reduce any treatment effects detected. In any case, these factors will apply equally to both treatment arms. WOSCOPS patients have not all been followed up to death and hence we cannot, without extrapolation, project to lifetime benefits. Nevertheless, it is all the more remarkable that we were able to demonstrate cost savings over a finite time period. In fact, this could be seen as an advantage as we avoid the need for extrapolating benefits to the complex situation at the end of life in the very old. While the events, hospital admissions, and deaths are observed, we had to estimate costs and quality-of-life impacts retrospectively. For acute costs, we selected national tariff rates and for utilities and incremental costs of events from a previously published independent health technology assessment report. We also subjected these assumptions to sensitivity analysis and have shown that if the figures are changed by 25% in a direction that reduces the cost-effectiveness of statin prescribing then our conclusions would be unchanged. Although an increase in the costs of pravastatin treatment and monitoring by a factor of 5 removed the cost savings in our analysis, this scenario is particularly unlikely given the fact that monitoring of patients is much less common in practice than we have assumed in the model and likely to become even less so because of recent FDA advice not to carry out long-term routine liver function monitoring. Our sub-group analysis by baseline risk is possibly underpowered. Nevertheless, if anything, there was a trend to greater cardiovascular cost savings in the lowest risk subjects.

Finally, our findings are limited to randomized allocation to placebo or pravastatin over 5 years. It seems inevitable that longer treatment with a statin, for instance lifetime treatment, which would be normal clinical practice, would yield greater cardiovascular health gains. However, we cannot say with certainty that this would be more cost-effective. In addition, although in this population of middle-aged men treated with pravastatin 40 mg/day, we found no evidence of increased risk of diabetes within the trial or of risk of hospital admission associated with diabetes or its complications in the 15 years of follow-up, we cannot extrapolate these safety findings to patients treated for much longer periods. Table 6Cumulative mean costs (per 1000 people treated) and quality-adjusted life years after 15 years, in those originally randomized to receive pravastatin or placebo, with mean, 95% confidence interval, and *P* value for the difference between randomized groups (pravastatin − placebo)PlaceboPravastatinDifference (Prava − Plac)Interaction *P* valueCardiovascular disease costs (£million/1000 people) All3.552.84−0.71 (−1.09 to −0.32), *P* \< 0.001 Low risk2.111.27−0.84 (−1.27 to −0.42), *P* \< 0.0010.85 Intermediate risk3.472.89−0.58 (−1.27 to 0.08), *P* = 0.086 High risk5.044.36−0.68 (−1.49 to 0.11), *P* = 0.088QALYs (per 1000 people) All11 05711 193136 (25 to 247), *P* = 0.017 Low risk11 90512 016111 (−12 to 238), *P* = 0.0790.95 Intermediate risk11 07511 207131 (−51 to 309), *P* = 0.17 High risk10 22010 371151 (−72 to 376), *P* = 0.18Non-Cardiovascular disease costs (£million/1000 people)) All6.006.030.03 (−0.44 to 0.52), *P* = 0.87 Low risk4.424.33−0.09 (−0.81 to 0.66), *P* = 0.830.65 Intermediate risk5.846.200.36 (−0.44 to 1.18), *P* = 0.37 High risk7.687.55−0.13 (−1.00 to 0.75), *P* = 0.78[^6]

Conclusions {#s5}
===========

Five years of treatment with pravastatin 40 mg of middle-aged men with hypercholesterolaemia and no history of myocardial infarction significantly reduced cardiovascular hospital admissions, incremental costs of events and net costs taking into account the cost of the drug and associated monitoring. Quality adjusted life years lived were significantly increased. There was no evidence of any increase in non-cardiovascular admissions or associated costs. These effects, seen across a range of underlying cardiovascular risks, suggest that treatment of even lower-risk individuals would still be economically efficient and deliver significant public health benefits. Our results add to and support a recent call for expanded use of statins.^[@EHT232C19]^ However, there remains uncertainty in relation to the potential for increased risk of diabetes with treatment of more than 5 years duration.
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Sensitivity analyses. Estimated difference (pravastatin---placebo, with 95% CI) between those originally randomized to receive pravastatin or placebo for the cumulative mean costs (per 1000 people treated) and QALYs after 15 years, under alternative scenarios. Costs include all cardiovascular hospitalizations and associated additional healthcare costs, plus pravastatin treatment and monitoring costs. Alternative scenarios are: hospitalization costs ±25%; additional healthcare costs ±25%; 50% reduction; and two- and five-fold increase in treatment/monitoring costs; QALY decrements ±25%. All costs and QALY decrements are discounted at 3.5%. Costs are given in units of £1 million. Costs (£) (per 1000 people)QALYsBase case−0.71 (−1.09 to −0.32)136 (25--247)Changes to hospitalization costs +25%−0.86 (−1.30 to −0.41) −25%−0.56 (−0.88 to −0.22)Changes to incremental costs of events +25%−0.78 (−1.20 to −0.36) −25%−0.64 (−0.98 to −0.28)Changes to treatment and monitoring costs /2−0.81 (−1.19 to −0.42) ×2−0.50 (−0.89 to −0.16) ×50.11 (−0.27 to 0.50)Changes to QALY decrements +25%153 (40--265) −25%120 (10--230)

[^1]: Hazard ratios (HR) (pravastatin vs. placebo), 95% confidence intervals and *P* values are derived from Cox proportional hazards models for time-to-first event analyses.

[^2]: MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CHD, coronary heart disease; HF, heart failure; CV, cardiovascular.

[^3]: All cardiovascular event type categories are mutually exclusive with periods of stay classified hierarchically as stroke if the period involved a stroke, otherwise as myocardial infarction (MI) if it involved myocardial infarction, otherwise as heart failure (HF) if it involved HF and otherwise as other coronary heart disease (CHD) if it involved another coronary heart disease event. The table also contains *P* values comparing the total length of continuous inpatient stay (***P*~T~**) and mean length of continuous periods of inpatient stay (***P*~M,~**comparing subjects in each group with at least one hospital admission)) between the randomized treatment groups.

[^4]: *P* \< 0.001, chi-square test.

[^5]: All cardiovascular event type categories are mutually exclusive with periods of stay classified hierarchically as stroke if the period involved a stroke, otherwise as myocardial infarction (MI) if it involved myocardial infarction, otherwise as heart failure (HF) if it involved HF and otherwise as other coronary heart disease (CHD) if it involved another coronary heart disease event. Also shown are estimated post admission incremental costs of events for cardiovascular admissions, and pravastatin treatment and associated lipid and safety monitoring costs within the pravastatin group. Costs are shown without and with discounting at an annual rate of 3.5%.

[^6]: Costs shown are for all cardiovascular admissions and incremental costs of events, plus treatment and monitoring costs, and for non-cardiovascular disease admission costs. Costs and quality-adjusted life years shown for all randomized subjects, and separately by thirds of cardiovascular risk. Interaction *P* values test whether between-treatment differences are equal across cardiovascular risk groups. All costs and quality-adjusted life year decrements are discounted annually at 3.5%. Costs are given in units of £1 million.
